ArticleAntimicrobial agents and chemotherapy2002
In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.
Article in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 77 citations in OpenAlex.
- Auranofin is active against Histoplasma capsulatum and reduces the expression of virulence-related genes.PLoS neglected tropical diseases · 2024Article
- Comparison of the antifungal activity of the pyrimidine analogs flucytosine and carmofur against human-pathogenic dematiaceous fungi.Medical mycology · 2024Article
- Repurposing Benzimidazoles against Causative Agents of Chromoblastomycosis: Albendazole Has Superior In Vitro Activity Than Mebendazole and Thiabendazole.Journal of fungi (Basel, Switzerland) · 2023Article
- Epidemiology, Modern Diagnostics, and the Management of Mucorales Infections.Journal of fungi (Basel, Switzerland) · 2023Review
- Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.Journal of clinical medicine · 2022Review
- Improved In Vitro Anti-Journal of fungi (Basel, Switzerland) · 2022Article
- New possibilities for chromoblastomycosis and phaeohyphomycosis treatment: identification of two compounds from the MMV Pathogen Box® that present synergism with itraconazole.Memorias do Instituto Oswaldo Cruz · 2022Article
- A screening of the MMV Pathogen Box® reveals new potential antifungal drugs against the etiologic agents of chromoblastomycosis.PloS one · 2020Article
- In Vitro and In Vivo Evaluation of Voriconazole-Containing Antifungal Combinations against Mucorales Using aJournal of fungi (Basel, Switzerland) · 2019Article
- Molecular identification and antifungal susceptibility profiles of clinical strains of Fonsecaea spp. isolated from patients with chromoblastomycosis in Rio de Janeiro, Brazil.PLoS neglected tropical diseases · 2018Article
- Heat shock protein 90 and calcineurin pathway inhibitors enhance the efficacy of triazoles againstMicrobial cell (Graz, Austria) · 2014Article
- The calcineurin pathway inhibitor tacrolimus enhances the in vitro activity of azoles against Mucorales via apoptosis.Eukaryotic cell · 2013Article
- Drug combinations against Mucor irregularis in vitro.Antimicrobial agents and chemotherapy · 2013Article
- Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.The Journal of infectious diseases · 2013Article
- Rhino-orbital-cerebral mucormycosis.Current infectious disease reports · 2012Article
- Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species.Clinical microbiology reviews · 2011Review
- In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.Antimicrobial agents and chemotherapy · 2009Article
- Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.Antimicrobial agents and chemotherapy · 2008Article
- Zygomycosis: an emerging fungal infection with new options for management.Current infectious disease reports · 2007Article
- Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.Antimicrobial agents and chemotherapy · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combinations of antimicrobial agents were tested against 35 strains of zygomycetes. The interaction between amphotericin B and rifampin was synergistic or additive. Flucytosine alone was inactive and, upon combination with amphotericin B, synergy was not achieved. The combination of amphotericin B with terbinafine was synergistic for 20% of strains, and the interaction between terbinafine and voriconazole was synergistic for 44% of strains. Antagonism was not observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.